CA3166158C - Amphiphilic polymers and their use for improved production of nanoparticles for the targeted delivery of antigens - Google Patents

Abstract

The present invention provides nanoparticles comprising a) a micelle comprising an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less, and b) at least one peptide comprising at least one T cell epitope. The present invention further provides pharmaceutical compositions comprising these nanoparticles and the use of the compositions for suppressing specific immune responses.

Description

AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS FIELD OF THE INVENTION The present invention provides nanoparticles for use in the prevention and treatment of autoimmune diseases, allergios or other chronic inflammatory conditions, and for generation of regulatory T cells. In particular, the present invention relates to nanoparticles comprising a micelle comprising an amphiphj lic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less, rendering the nanoparticle water-soluble, and at least one peptide comprising at least one T cell epi tope. The present invention also relates to a pharmaceutical composition comprising the nanoparticles. The pharmaceutical composition can be used for generating regulatory T cells specific to at least one T cell epitope in a subject for treating or preventing a disease wherein suppression of a specific immune response is beneficial.

Furthermore, the present invention provides a method for lhe production of the nanoparticles.

BACKGROUND OF THE INVENTION Autoi:rrrmune diseases represent a substantial burden for patients and healthcare systems. Current therapies rely mostly on lmmunosuppressive drugs with considerable:: side effects.

Autoantigen-specific immunotherapies that exclusively target disease-specific -immune pathologies leaving the generul immune status untouched represent an unmet medical need.

Immune tolerance mechanisms that to self-antigens is maintained control potentially pathogenic by multiple autoreactive lymphocytes, including deletion, clonal anergy or suppression by regulatory T cells. Autoimmune disease may thus result from insufficient control of autoreactive lymphocytes, and a major goal of immunothc::rapy for autoimmune diseases is the induction of tolerance to autoantigens by restoring regulation. A 1 CA 03166158 2022-7-26 particularly promising way to restore self-tolerance seems to be the manipulation of autoantigen-specific CD4+CD25+FOXP3+ regulatory T cells. The adopllve transfer of these cells can prevent autoimmune or inflammatory conditions.

The liver plays a central role in the suppression of unwanted immune responses against blood-borne antigens, e.g. food antigens, enterlng the circulation. of the liver can be employed to This fnndarrental mechanism specifically downregulate detrimental immune responses against external protein antigens or autoantigens. Antigenic peptides derived from such proteins, when coupled to nano-sized carriers and administered intravenously, mimic food antige:::1.s triggering uptake by specific liver cells, "':=he liver sinusoidal endothelial cel::...s (LSECs), followed by a tolerogenic lrnmune response. Peptidespecific immune tolerance can thus be induced for defined immune d-i sease-causing antigens, leading to the ameliorallon or even eradication of detrimental immune reactions. This 2pproc1ch can thus also be used to preventive setting. be used to prevent treat ongoing the respective diseases diseases and may in a For example, ectopic expression of a neuroant-igen in the liver can prevent autoimmune neuroinflammation in mice with experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). This finding can be explained by the capacity of the liver to generate neuroantigen-specific regulatory T cell:s (Tregs) that have a profound ability to control and suppress autoimmune responses.

LSECs play a crucial role for achieving this effect. LSECs express MHC/HLA class I a.nd class II molecules on their surface and thus have the capacity to present peptides tc both, CD0+ (via cross-presentation) and CD4+ T cells, respectively. Peptide-antigen presentation by LSECs converts naive and T effector cells to Tregs in an antigen-specific way in vi tru. Thl:s _1_s apparently the physiological mechanism by which LSECs can establish tolerance against blood-borne anligens. 2 CA 03166158 2022-7-26 Nar:oparlicles conjugated with a disease-specific antigenic peptide to Lhe particle surface, like blood-borne antigens, target the liver after intravenous injection. Upon uptake by LSECs, presumably by pinocytosis, the nanoparticles accumulate in the endosomal compartment where the peptide antigens are released from the surface of the particles. This leads to the presentation of those antigenic peptides at the LSEC surface, mediated by MHC/HLA molecules. There is evidence that the subsequent generation of Tregs confers immune tolerance specific for the respective nutonntigen based on its antigenic peptide epitopes.

WO 2 00 9/ 067 349 discloses a pharmaceutical composition comprising a biocompatible nanoparticle linked to an aryl hydrocarbon receptor (AHR) transcription factor ligand for use in the treatment of autoirrrrcune disorders by increasing the number and/or activity of regulatory T cells.

WO 2013/072051 discloses a pharmaceutical composition for use in generating regulatory T cells specific to at least one T cell epitope in a sGbject for treating or preventing a disease wherein suppression of a specific immune response is beneficial. The nanoparticle comprises a micelle cumprl:::ilng an amphiphilic polymer rendering the nanoparticle water-soluble, and a peptide comprising at least one T cell epi tope associated with the outside of the micelle. It is generally suggested to use commercially available poly(maleic anhydridealt- 1-ocladecene as amphiphilic polymer having a molecular mass of 30,000 to 50,000 g/mol and about 90% purity.

However, in certain medical applications it is imporranr ~hat the nanoparticles can be produced with a very high degree of purity using efficient purification methods.

There still is a need in the u.rt for improved nanoparticles for treating and preventing a disease wherein suppression of a specific imr:mnc response is beneficial, e.g. in autoimmune diseases, in allergies, in transplantation, in the suppression of anti-drug-antibodies (ADA) ngainst therapeutics or gene vectors, or in a disease wherein inflammation is excessive, 3 CA 03166158 2022-7-26 chronic or adverse, and wherein said pharmaceutical composition is suitable for use in human subjects.

SUMMARY OF THE INVENTION According to the present invention the above problems are solved by a nanoparticle comprising a) a micelle comprising an amphiphilic polymer with a number average molecular weiqht (Mn) of 20,000 q/mol or less, and b) at least one peptide comprising at least one T cell epitope.

The inventors comprising an molecular weight have surprisingly found that nanoparticles amphiphilic polymer with a number average (Mn) of 20,000 g/mol or less can be produced more easily and to a higher degree of purity.

Without being bound to a theory underlying the effects of the nanoparticles of the present invention, it is presently understood that upon uptake of the nanoparticles by LSECs, the at least one peptide associated with the outside of the rnicelle is released, either by hydrolysis, proteolysis or other activities in the endosomes, processed as if it was a blood-born ant.-i gen, and presented to T ce.l ls in a tolerogenic environment. ?he low molecular weight amphiphilic polymer enables excretion of individual polymer molecules upon release in vivo. This provides for hep a tobi liary excretion, which appears to represent the preferred excretion pathway for nanoparticles.

It has been surprisingly found that low molecular weight amphiphilic polymers having a number average molecular weight (Mn) of 20,000 g/mol or less can easlly be excreted. It is also expected that low molecular weight amphiphilic polymers and their metabolites are rapidly eliminated from the body after treatment.

The inventors have surprisingly found that the low molecular weight amphiphilic polymer has advantageous properties during 4 CA 03166158 2022-7-26 production of the nanoparticles of the present invention. The low molecular weight amphiphilic polymer produces fewer aggregates during coating of a solid core than a high molecular weight amphiphilic polymer. In addition, the low molecular weight amphiphilic polymer can be purified more efficiently compared to a high molecular weight amphiphilic polymer. In particular, unbound polymer can be separated more efficiently when a low molecular weight amphiphilic polymer is used in the nanoparticle of the invent~on.

The invention further provides a pharmaceutical composition comprising the nanoparticle.

The present invention also provides a pharmaceutical composition comprising the nanoparticle for use in generating regulatory T cells specific to at least one T cell epitope in a subject for treating or preventing a disease wherein suppression of a specific inunune re::,pun::,e i~ beneficial.

Finally, the present inve~tion provides a method of producing a nanoparticle comprising: i) ohlaining an amphiphilic average molecular weight less, polymer (Mn) of with 20,000 a number g/mol or ii) optionally purifying the amphiphilic polymer, iii) forming micelles of the amphiphilic polymer, iv) adding at least one peptide to form the nanoparticles.

BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a flow chart showing lhe synthesis of an iron oleate complex.

Figure 2 lS a flow chart showing superparamagnetic iron oxide nanoparticles CA 03166158 2022-7-26 the synthesis (SPIONs). of Figure 3 is a f~ow molecular weight poly PMAOD). chart showing Lhe synthesis of (maleic anhydridc-alt-1-octadecene) Fig-ure 4 molecular PMAcOD) . is a flow chart showing the synthesis of weight poly(maleic acid-alt-1-octadecene) low (LMlow (LMFigure 5 is a flow chart showing the polymer coating of SPIONs.

Figure 6 is a flow chart showing the coupling of peptides to the nanoparticles of the present invention.

Figure 7 shows transmission of nanoparticles of magnification) electron microscopy (TEM) the present invention images (l00x Figure 8 is a grctph representing the molecular mass distribution of LM-PJV.LA.cOD as determined using gel permeation chromatography and polyslyrene as a calibration standard.

Figures 9 to 11 illustrate SEC chromatograms purification of 2~-PMAcOD-SPION samples. of the Figure 12 shows the results of size exclusion chromatography of the purification LM-PMJ\.cOD-SPION samples.

Figure 13 coating. shows SEC chromatograms of the products after DETAILED DESCRIPTION OF THE INVENTION According to the present invention nanoparticles are provided which comprise a micelle comprising an amphiphilic polymer with u number average molecular weight (Mn) of 20,000 g/mol or less rendering the nanoparticle water-soluble, and at least one peptide comprising at least one T cell epitope. The nanoparticles may further comprise a solid hydrophobic core which is coated by the micelle.

According to the present application, the term "nanoparticle" is used interchangeably with "nano scale particle". Such 6 CA 03166158 2022-7-26 WO 2021/165227 particles have a diameler of 1 to 999 nm, 6 0 0 nm, 5 to 5 0 0 nm, 1 0 to 3 O O nm, 3 0 to nm.

PCT/EP2021/053711 preferably, of 2 to 100 nrr. or 40 to .:i0 In the context of the present invention, a nanoparticle is a structure formed by at least a micelle and a peptide which is associated to the micelle. The peptices may either be associated to the outside of the micelle or encapsulated inside the micelle.

In an embodiment of the present invention, the nanoparticles ot· the present invention comprise a solid hydrophobic core, a micelle coating the core comprising an amphiphilic polymer with a number average molecular weight (Mn) oi 20,000 g/mol or less rendering the nanoparticle water-soluble, and at least one peptide comprising at least one T cell epitope.

The micelle In the context of the present invention, tho term "micelle" relates to an aggregate of amphiphilic molecules dispersed in an aqueous solution. The hydrophilic parts of the amphiphilic molecules are in coLtact with the surrounding solvent, sequestering the hydrophobic r1tail n regions of the amphiphilic molecules on the inside of the micelle, and thus render the nanopc1rticle water-soluble. This type of micelle is also known as a normal phase micelle (or oil-in-water micelle).

The micelle can be formed by one, but also by more than one, e.g., two, three or four amphiphilic polymeric molecules. The micelle can be formed by the same or by different amphiphilic polymeric mol8cules. ln general, in the context of the specification, "a" or "the" is not intended to be limiting to "one" unless specifically stated.

In 2 preferred embod~ment, the micelle is formed by a single layer of amphiphilic polymers.

Such a micelle can be structurally distinct from a bilayer or a liposome formed by an amphiphilic polymer. In this case the structures are not, or not to a significant percentage (e.g. 7 CA 03166158 2022-7-26 not more than 10%, more than 5%, or preferably, more than 1%), comprised in tne nanoparticle of the present invention.

In one embodiment of the present invenllon, Lhe amphiphilic polymer is used to produce at least 70%, preferably at least 90% of the micelle. In a preferred embodiment, the micelle consists of the amphiphilic polymer.

In some embodiments cf the present invention the nanoparticles do not comprise a solid hydropholilc core. Iu other embodiments, the nanoparticles comprise the rniccllc and a solid hydrophobic core.

Methods of producing the nanoparticles invention are described in detail bellow.

The amphiphilic polymer of the present The amphiphilic polymer of the present invention generally comprises a hydrophobic region comprising a hydrophobic aliphatic chain having a length of 8 to 2 3, preferably 8 to 21, most preferably 16 to 18 carbon atoms.

The hydrophil:ir: region of the amphi philic polymer may be negatively charged in an aqueous solution.

In a preferred embodiment of the present invention, the amphiphilic polymer spontaneously forms micelles in solution.

When a solid hydrophobic core is present, the amphiphilic polymer forms micelles around the solid core, rendering the nanoparticle water-soluble.

The number average molecular weight (Mn) of the amphiphil::_c polymer is 20,000 g/mol or less, preferably 10,000 g/mol or less, or 6,000 g/mol or less, more preferably from 6,000 to 1,000 g/mol, most preferably from 3,000 to 6,000 g/mol.

The number average molecular weight may be determined using gel permeation ch~omatography (GPC), preferably using polystyrene as calibration standard.

In a preferred embodiment the number average molecular weight is determined using a PL-gel mixed D column at a temperature 8 CA 03166158 2022-7-26 of 40°C, a mobile phase consisting u:C letrahydrofuran/acetic acid 90/10% (v/v), a flow rate of 1. 0 ml/min, in combination with a refractive index detector at a temperature of 35°C and polystyrene as calibration standard.

In the most preferred embodiment, the determination of -=he number average molecular weight uses GPC and the following measurement conditions: Reference standards Polystyrene standard (MW (nominal Mp); 1000 g/mol to 130000 g/mol Agilent PL-gel mixed-D, 300 X 7.5 mm Column ID, 5 μm Column Temperature 40°C Detector Refractive index detector at 35°c Flow rate 1.0 ml/min Injection volume 20 μL Autosampler te:'Ilperature Ambient Run time 15 min Tetrahydrofuran/Acetic acid Mobile phase [90/10]%(v/v) Mobile phase program Isocratic The amphiphilic polymer may be an alternating copolymer. An alternating copolymer is a copolymer comprising two species of monomeric units distributed in ulternuting sequence.

In one embodiment of the present invention, the amphiphilic polymer is a copolymer of maleic anhydride and at least one alkene.

The alkene used in the p::::-oduction of the amphiphilic polymer may be selected from one or more of 1-decene, 1-undecene, 1- dodecene, 1-tridecene, 1-tetradecene, 1-pentadecene, 1- hexadecene, 1-heptadecene, 1-octadecene, 1-nonadecene or 1- eicosene, preferably the alkene is 1-octadecene.

In a preferred e=nbodiment of the present invenlion, the amphiphilic polymer is a copolymer of maleic anhydride and aL alkene. 9 CA 03166158 2022-7-26 ln a preferred embodiment of the present invention, the amphiphilic polymer has a main hydrophilic poly-maleic anhydride backbone having hydrophobic alkyl side chains.

Typically, the side chain can have from 5 to 23 carbon atoms, in particular from 9 to 21 atoms. In a most preferred embodiment, the side chains are linear and have from 10 to 18 carbon atoms.

The amphiphilic polymer may comprise the following building block OH HO wherein Risa hydrocarbyJ group or a substituted hydrocarbyl group. In a preferred embociiment of the present invention, R is a C4 to C22 alkyl group, such as a C, to C19 alkyl group.

In an even more group, preferably pn:,f P.rnhly R is n group. preferred embodiment, R is a a linear C7 to C17 alkyl linP.nr penti'l_cler:yl gronp or a linear group, 1 i near alkyl most n:-:inyl The amphiphilic polymer may consist of the building block defined above. ln other embodiments according to amphiphilic polymer comprises at least 7 O % , most preferably more block detined above. the present invention, the least 50 i, than 90 % of preferably at the building Jn a preferred embodiment, the amphiphilic polymer is selected from the group comprising poly(maleic acid-1-octadecene), poly(maleic acid-1-tetradecene) or poly(maleic acid-1- dodecene), preferably the polymer is poly(maleic acid-1- octadecene) and the number average molecular weight of the polymer is from 6,000 to 1,000 g/mol.

In a specifically polymer is selected CA 03166158 2022-7-26 preferred from the embodiment, the group comprising amphiphilic poly(maleic acid-alt-1-octadecene), poly(maleic acid-alt-1-dodecene) and poly(maleic acid-alt-1-tetradecene), preferably the polymer is poly(maleic acid-alt-1-octadecene) and the number average molecular weight of the polymer is from 5000 to 1000 g/mol.

Methods of producing the amphiphilic polymer of the present invention are also described in detail below.

The peptides The nanoparticle of the present invention further comprises at least one peptide comprising at least one T cell cpitopc. The peptide may be associated with the outside of the micelle or encapsulated in the inside of the micelle (in embodiments where no solid hydrophobic core is present in the nanoparticle of the present invention) . Accordingly, the peptide may be localized on the outside of the micelle or inside the micelle.

The peptjde may be covalently 7 inked to the micelle or noncovalently associated, preferably covalently linked to the micelle.

In a preferred embodiment, the peptide is covalently linked to the micelle using a method of covalently coupling peptides known in the art such as carbodiimide or succinimide coupling.

Preferably, the peptide is covalently linked to tl:e micelles using l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry.

In the context of the present invention, the term ~peptide" is not intended to be limiting in sjze, in particular, the peptide may comprise a whole protein or 8 to 2,000 amino acids, preferably, 8 to 200 amino acids, 8 to 100 amino acids, 9 to 60 annno acids, or 10 Lo 2 0 amino acids. The term also comprises combinations of different peptides, which may be linked to each other as fusion polypeptides.

In a preferred embodiment of the present invenlion, the peptide comprises 10 to 20, such as 13 to 17 amino acids.

In a specifically preferred embodiment, the peptide comprises 15 amino acids. 11 CA 03166158 2022-7-26 The peptide comp=ises at least one T cell epitope. Methods for identifying T cell epi topes and selected T cell epi topes a=e well known in the art and described for example in the publications of Rammensee et al., 1999 (Immunogenetics 50 213- 219) and Sanchez-Trincado et al. 201 7 (J Immuno_'._ Res. 2017:2680160. doi: 10.1155/2017/2680160. Epub 2017 Dec 2B) In the context of the present invention a T cell epitope is a peptide sequence inducing regulatory T cells. At least one epitope needs to be capable of being presented by cells of the subject to which the nanoparticles are to be administrated. Preferably, t:t.e peptide comprises several epi topes which enable it to be presented in a plurality of Major Histocompatibility Complex types.

As the regulatory T cells are predominantly CD4+, presentation on MHC class TT .is of ma.i.n interest. The HLA type of this subject, e.g., a human subject, and can easily be tested as part of the selection of epi topes. Epi topcs of a specific peptide which can be pr8scntcd on specific MHC molecules ure known and/or can routinely be selected, e.g., by uppropric1te software.

Peptides are designed based on published data to make sure that they - in association with the specified HLA restriction element bind MHC/HLA with high affinity and profoundly stimulate and activate 'l' cells. Ideally, peptides of choice are inferred from naturally processed peptides and characterized as immunodominant.

The peptide may be synthesized, recombinantly expressed or isolated or modified from natural sources. The peptide, or at least the epi tope against which regulc.1.tory T cells are c:=o be generated, is preferably derived from a peptide/protein against which an inflammatory immune response is to be suppressed, e.g., in the coI'-text of treatment or prevention of an autoimmune disease or an allergy. The peptide may, e.g., be an allergen, a known autoimmune antigen, or a fragment or derivative thereof. The peptide can combine various epi tapes from various antigens. 12 CA 03166158 2022-7-26 ln a preferred embodiment of the present invention, the peptide is an antigenic peptide derived from Desmoglein-3 (Dsg3) . For example, the peptide may be one or more Lhan one of the Desmoqlein-3 peptices characterized by SEQ ID NOs:1-3.

According to one embodiment of the present invention, the nanoparticles comprise only one type of peptide comprising at ~east one T cell epitope.

According to a further embodiment the present invention provides a composition comprisinq different nanoparticles, wherein each nanoparticle comprises numerous peptides having the same amino acid sequence but the composition comprises mixlures ot nanoparticles which differ from each other in the peptide sequence. The composition may for example comprise different nanoparticles comprising 2 to 6 different peptides.

In one aspect, the composition of different nanoparticles may comprise three different types of nanoparticles, each characterized by one of SEQ ID NOs:1-3.

The solid hydrophobic core In one embodiment of the present comprises a solid hydrophobic core by the micelle. invention the nanoparticle at least partially coated The core can be an inorganic core, preferably comprising iron oxide, CdSe, silver or gold.

The diameter of the core may be 2 to 500 nm, preferably, 3 to 25 run, more preferably, 5 to 15 nm. The diameter of the core may be determined using transmission electron microscopy (TEM) or small-angle X-ray scattering (SAXS).

Exemplary inorganic stabilized by oleic preferably, cores acid or quantum are iron oxide another carboxylic dots (CdSe/CdS/ZnS nanopart.icles acid (C14-C22, stabilized, e.g., by trioctyloxinphosphinuxide), gold nanoparticles, e.g., stabilized by sulfonic compounds.

Such inorganic cores by themselves are typically not stable in an aqueous solvent such as water, but embedding them in the 13 CA 03166158 2022-7-26 polymeric micelles renders them water-soluble. The hydrophobic parts of the amphiphilic polymer interact with the hydrophobic core of the nanoparticle, leading to formation of a single coating layer of polymer surrounding the core. In the coating process the amphiphilic polymer can replace the hydrophobic part of the core by ligand exchange and the double layer micelle is thus formed around the core. In one embodiment of the invention, the polymer at least partially replaces the olcic acid on the surface of the core particle and the hydrophilic part of the polymer interacts with the surface of the iron oxide core and the hydrophobic part of the polymer interact with each other forming a double layer micelle around the iron oxide core, resulting in an iron oxide coated with polymer.

According to a preferred embodiment of the present invention, the core is superparamagnetic.

In a specifically preferred embodiment of the present invention, the co::::-e is a superparamagnetic iron oxide nanoparticle (SPION), which may be stabilized by oleic acid.

The ~ores preferahJy render the nanoparticles of the invention traceable, e.g., by their characteristics in fluorescence, electron microscopy or other detection method.

The nanoparticles The inventors have found that nanoparticles for use in the present invention are suitable for transferring the peptide to liver sinusoidal endothelial cells of a subject in vivo.

The nanoparticles may additionally comprise a moiety, e.g., a carbohydrate or a protein targeting them, or enhancing targeting to specific cells such as liver sinusoidal endothelial cells and/or Kupffer cells. Such moiety could, e.g., enhance or accelerate uptake from the circulation via receptor mediated endocytosis. Examples of suitable modifications are carbohydrates such as mannose.

The nanoparticle, by virtue of Lhe micelle, may be negatively charged or 14 CA 03166158 2022-7-26 polymer forming the uncharged; preferably, the nanoparticle is negatively charged at a pH of 6 to 7. The polymer coating may comprise acid, e.g., carboxylic acid, groups, leading to a negative charge of the nanopartic~e. 'i'he nanoparticles of the present invention may have a zeta potential between -20 and -50 mV, preferably between -25 and -4.5 mV, more preferably between -28 and -42 mV at pH 6 to 7 (pH during measurement) . The zeta potentinl can be using a Malvern Zetasizer Nano ZS instrument.

The nanoparticles of hydrodynamic diameter the present invention may (z-average) between 10 and 100 measured have nm or a and 70, preferably between 10 anti 50, more preferably between 20 and 40 m, mos~ preferably between 22 and 32 nm, as measured by dynamic light scattering (DLS).

The nanoparticles of the present invention may have a polydispersi ty index below 0. 50, preferably between 0. 05 and 0. 45, more preferably between O .10 and O. 40, as measured by dynamic light scattering (DLS).

The determination of the hydrodynamic diameter and the polydispersity index is carried out light scattering analysis methods, using electrophore~ic preferably a Malvern Zetasizer. In one errbodimcnt the method for de Lermining the hydrodynamic diameter and the polydispersity index is carried out using electrophoretic light scattering, disposable polystyrene cuvettes, Zetusi zer Software 7. 12, milli-Q water.

The nanosphere size standards of 20 nm and 100 nm (NIST certified or equivalent) are diluted in an aqueous 0.9% sodium chloride solution and the test samples are diluted in water.

All aqueous reagents are filtered through O. 2 2 μm membrane prior to use. In the most preferred embodiment of the invention, the method for determining the hydrodynamic diameter and the pulydispersi ty index is carried electrophorctic light scattering in combinution following analysis conditions: CA 03166158 2022-7-26 out using with the Overview of the analysis conditions: Parameter Setting Dispersant name Water Dispersant ~I 1. 33 Viscosity (CP at 25,0 OC) 0.8872 Material RI (sample) 2.42 Material RI (standards) 1.333 Material Absorption 0.05 Temperature ( o C) 25 Measurement Position 1.65 (mm) Cell description Disposable sizing cuvette Attenuator Auto Measurement duration Auto The evaluation of the data is based on mean diameter (ZAverage, nm by intensity), which is a parameter also known in DLS as the curnulants mean and Polydlspersi ty index ( PDI) , which is used as a measure of the size distribution.

Furthermore, the nanoparticles of have a total polymer content of 0.1 to 4 mg/mL, more preferably of 1 to the present invention may to 5 mg/mL, preferably 0.5 3 mg/mL. The total polymer content is determined by GPC. For measuring the total polymer content, the peptides are hydrolyzed, c1nd the particles are destroyed (e.g using a 6 M HCl solution) The polymer is extracted after addition of EDTA. After evaporation of solvent, the residue is re-ciissolved and the polymer content is determined by GPC.

The determination of total polymer content is preferably carried out using the following reagents and reference standards water (HPLC grade), acetonitrile (HPLC grade), tetrahydrofuran with BHT ( THF-HPLC grade) , acetic acid 1 O O % (analytical grade) , hydrochloric acid 37% (analytical grade), ethylenediaminetetraacetic acid disodium salt dihydrate (analytical grade), ethyl acetate hydroxide (analytical grade) and octadecene) as reference material. 16 CA 03166158 2022-7-26 (analytical grade), sodium poly(maleic acid-alt-1- The chromatograp:1.ic conditions for the determination ot total polymer content are: Column Agilent PL-gel Mixed-D, 300+75 mm ID, 5μm Column temperature 4C°C Flow rate l. 0 mL/min Detector Refractive index detector at 35°c Sample rating 2.31 Hz or equivalent Injection volume 20 μL Autos ampler temperature Arrbient Run time 15 min Mobile phase THF/Acetic acid [90/10]%(v/v) Mobile phase program Isocratic In a specifically preferred invention, the nanoparticles encapsulated by a coating embodiment of comprise an iron of poly(maleic the present oxide core acid-alt-1- octadecene) having 6,000 to 1,000 g/mol one T cell epitope a number average molecular weight from or less and a peptide comprising at least peptide which is preferably covalently linked to the micelle.

In one aspect the present invention thus provides nanoparticles comprising a) a micelle comprising an amphiph.ilic polymer comprising the following b~ilding block wherein R is a hydrocarbyl group or a substituted hydrocarbyl group, preferably R is a linear alkyl group, preferably c1 linec1r C11 to Cn c1lkyl group, and wherein the polymer has a number average molecular weight (Mn) of 6,000 to l,COO g/mol, and b) at least o~e peptide comprising at least one T cell epi tope; and 17 CA 03166158 2022-7-26 I I I c) a solid hydrophobic core which is at least partically coated by tho micelle, wherein the core comprises a traceable inorganic material selected from Lhe group comprising iron oxide, CdSe/CdS/ZnS, silver and gold.

The number average molecular weight preferably from 6,000 to 1,000 g/mol. of the polymer is The nanoparticle preferably has a hydrodynamic diameter between 50 and 10 nm as measured by dynamic light scaLLer..Lng.

The pharmaceutical composition The invention further provides a pharmaceutical composition comprising nanoparticles of the present invention.

The pepl..Ldes used may be present in the phurmaceutical composition in a concentration from O. 01 to 2 mM, preferably from 0.1 to 1 mM, mos~ preferably 0.45 mM to 1 mM.

In a preferred polymer than 5%, embodiment, polymer. in the composition is most preferable less the amount of less than 10%, than 7.% of the free (unbound) preferable less total amount of The pharmaceutical composition of the present invention may further comprise at least one suitable excipient and/or diluent. The diluent is preferably water or water-based, e.g., a buffer such as Phosphate buffered saline (PBS), Ringer solution, TRIS buffer or sodium chlor:i de solution. Sui table preservatives may or may not be contained. 1 t is evident that, in particular tor administration to a human SlJbj ect, the composition preferably is sterile and biologically compatible.

In a preferred embodiment of the present invention, the pharmaceutlcal composition comprises the nanoparticles of the present invention dispersed in D-mannitol, TRIS and/or Llactic acid.

In an embodiment of the present invention, the pharmaceutical composition comprises nanoparticles of the present invention 18 CA 03166158 2022-7-26 which do not comprise a solid hydrophobic core, which nanoparticles are dispersed in D-mannitol, TRIS and/or Llactic acid. The use of this buffer has the advantage that Lhe particles are very stable in this buffer and can be lyophilized later on.

Furthermore, the pharmaceutical composition may comprise more than one type of nanoparticle of the present invention, wherein the different types of nanoparticles have different peptides associated with the outside of the micelle. By using a mixture of nanoparticles, broader immune tolerance can be induced by several autoantigenic peptides at the same time.

These peptides may be derived from a single immunogenic protein, or from different proteins.

In a preferred embodiment of the present invention, the pharmaceutical composition comprises between 2 and 6 different types of nanoparticles, wherein preferably all associated peptides of the different types of nanoparticles comprise at least. one T cell epiLope.

In a specifically preferred embodiment of the present invention, the pharmac:eutical c:omposi tion c:omprisP-s hetween :=i and 4 different types of nanoparticles, wherein all as sod ated peptides of the different types of nanoparticles comprise at least one T cell epitope. In particular, each nanuparticle may be associated wi~h a different antigenic peptide derived from Dsg3.

The pharmaceutical composition may comprise the nanoparticle in a concentration below 100 μM, preferably from 0.5 to 80 μM, most preferably from 1 to 50 μM. If more than one nanoparticle is present in the pharmaceutical composition, each may be present in a concentration below 100 μM, preferably from O. 5 to 80 μM, more preferably from 1 to 50 μM.

The pharmaceutical composition of the present comprise different types of nanoparticles concentration. 19 CA 03166158 2022-7-26 invention may in equirnolar In one aspect the present invention thus provides a pharmaceutical composition comprising nanoparticles comprising a) a micelle comprising an amphiphilic polymer comprising the following building block wherein R is a hydrocarbyl group or a substituted hydrocarbyl group, preferably Risa linear alkyl group, preferably a linear C11 to C17 alkyl group, and wherein the polymer has a number average molecular weight (Mn) of 6,000 to 1,000 g/mol, and b) at least one peptide comprising at least one T cell epitope; and c) a solid hydrophobic core which is at least partically coated by the micell e, wherein the core comprises a traceabJe inorganic material selected from the group comprising iron oxide, CdSc/CdS/ZnS, silver and gold.

The number average molecular weight of the polymer 1 n the pharmaceutical composition will preferably range from 6,000 to 1,000 g/mol.

The nanuparlicles present invention in Lhe pharmaceutical composition of the preferably have a hydrodynamic diameter between !-JO arid 10 nm as Treasured by dynamic light scattering.

In a preferred aspect the present invention provides pharmaceutical composition comprising at least three different types of nanoparticles, wherein each nanoparticle comprises a) a micelle comprising an amphiphilic polymer comprising the following building block CA 03166158 2022-7-26 wherein R is a hydrocarbyl group or a substituted hydrocarbyl group, preferably R is a linear alkyl group, preferably a linear C11 to C17 alkyl group, and wherein the polymer has a number average molecular weight (Mn) of 6,000 to 1,000 g/mol, and b) one peptide comprising at a T cell epitope; and c) a solid hydrophobic core which is at least partically coated by the micelle, wherein the core comprises a traceable inorganic material selected from the group comprising iron oxide, CdSe/CdS/ZnS, silver and gold; and wherein the three different types of nanoparticles differ among each other in the peptide sequence, wherein the first type of nanoparticles comprises peptides having SEQ ID NO: 1, the second type of nanoparticles comprises peptides having SF.Q ID NO:2 and the third type of nanoparticles comprises peptides having SRQ TD NO:3.

The medical use The pharmaceutical intended for use subject having a composition of the present invention is in and formulated for administration to a disease wherein suppression of a specitic immune response is beneficial.

The pharmaceutical compositions may be administered to a subject in need thereof.

The required dose and concentration for administralion to the subject may be determined by the responsible medical attendant according to the facts and circnrnstances of Lhe case. An exemplary dose might comprise 0.03 μmol to 0.90 μrnol per patient body weight, e.g., for a human subject.

Administration may be repeated, e.g., times, e. g. , with, 1, 2, 3, 4, 5, 6, 7, administrations. twice, three or four 10 or 14 days between Preferably, the pharraaceutical composition is for use in suppressing a specific immune response, such as treating or preventing a disease wherein suppression of a specific immune 21 CA 03166158 2022-7-26 response is beneficial. More preferably, the pharmaceutical composition is for use in generating regulatory T cells specific to at least one T cell epitope in a subject. for treating or preventing a disease wherein suppression of a specific immune response is beneficial.

The disease can be an autoimmune disease associated with defined autoantigens. In the context of the present invention the term "autoimmune disease" is understood defined by Hayter et. al. (Autoimmunity Reviews 11 (2012) 754-765). In a preferred embodiment, the autoimmune disease is selected from the group comprising Pemphigus vulgaris, Pemphigus foliaceus, Epidermolysis bullosa Acquisita, Dullous pemphigoid, Cicatricial pemphigoid, Goodpasture syndrome, polyc1ngii tis, Crc:.mulomatosis with polyangii tis Microscopic (Granulom.

Wegener) , Thrombotic thrombocytopenic purpura., Immune thrombocytopenic purpurc1, Uvei tis, HLA-B27-associated acute anterior uveitis, Multiple sclerosis, Neuromyelitis optica, Type I diabetes, Narcolepsy with or without cataplexy, Celiac disease, Dermatitis herpetiformis, Allergic airways disease/Asthma, Myasthenia gravis, Hashimoto thyreoiditis, Autoimmune thyroid disease, Graves disease, Autoimmune thyroid disease, Autoimmune Hypoparathy~oidism, Autoimmune thyroid disease, Antiphospholipid syndrome, Autoimmune Addison's Disease, Autoimmune haemolytic anaemia, Chronic inflammatory dernyelinating, Polyneuropathy, Guillain-Barre Autoimmune neutropenia, Linear morphea, Batten Acquired syndrome hemophilia (acquired A, Relapsing neuro-myotonia) , polychondritis, syndrome, disease, Isaac's Rasmussen encephalitis, Morvan syndrome, Stiff-person syndrome, Pernicious anaemia, Vogt-Koyanagi-Harada syndrome, Primary biliary cirrhosis, Autoimmune hepatitis type I, Autoimmune hepatitis type ll, Systemic lupus erythematosus, Rheumatoid arthritis, Polymyositis/ Dermatomyositis, Sjogren syndrome, Scleroderma, Vitiligo and Alopecia areata.

More preferably, the autoinunune disease is selecl:ed from Lhe group comprising Pcmphigus vulgaris, Goodpasture syndrome, Microscopic polyangiitis, Thrombotic thrombocytopenic purpura, Multiple sclerosis, Neuromyelitis optica, Type I diabetes, 22 CA 03166158 2022-7-26 Narcolepsy with or cataplexy, Celiac disease, Autoimmune Addison's Disease, Autoimmune haemolytic anaemia and Acquired hemophilia A.

According to the prcsGnt invention, used to refer to the alleviation of the term "treating" is symptoms of a particular disease in a subject, and/ or improvement of an ascertainable measurement associated with a particular disorder.

The method of producing the arnphiphilic polymer and the nanoparticles Methods of producing the amphiphilic polymer and nanoparticles comprising the same are illustrated in Examples 1-1.

One method of obtaining the amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less resides in synthesizing the same using a two step method, comprising a step of producing a polymer of the anhydride and a step of hydrolyzing the anhydride to obtain an acid. The step of hydrolyzing the anhydride form of the polymer to obtain an acidic form can be illustrated as follows: base n 0 R OH HO n The present invention also provides a method of producing a nanoparticle comprisinq: i) obtaining an amphiphilic polymer with a number average molecular wcighl (Mn) of 20,000 g/mol or less, ii) optionally purifying t~e amphiphilic polymer, iii) forming micelles of thP- amphiphilic polymer, and iv) adding at least one peptide to form the nanoparticles.

In embodiments of the present invention in which the peptides are encapsulated by the micelle, step iv) is performed prior 23 CA 03166158 2022-7-26 to step iii). In these embodiments, the peptides are added to the amphiphilic polymer prior to micelle formation.

The amphiphilic polymer present invention may be used in the nanoparticles prepared (step i) by a. copolymerization using a radical initiator. of the radical The molecular weight of the polymer can be controlled by varying the concentrations of the reactants or the amount of radical initiator. The molecular weight of the polymer can be analyzed by gel permea.tion chromatography.

The copolymeri zation may be conducted in an organic sol vent such as 1,4 dioxane, xylene or chlorobenzene.

Many radical initiators a:::::-e known in the art; they include various peroxides and azo-type compounds. Examples of suitable peroxides are benzoyl peroxide, lauryl peroxide, di-t-butyl peroxide, 2, 4-dichlorobenzyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, diacetyl peroxide, diethyl peroxycarbonate, t-butyl perbenzoate and perborates. Sui table azo-type compounds include 2,2'-Azobis(2-methylpropionitrile), p-bromobenzenediazonium fluoborate, p-bromobenzenediazonium hydroxide, diazonium halides. Preferably, the Azobis(2-methylpropionitrile). p-tolyldiazoaminobenzene, azomethane and phenylradical ini~iator is 2,2'- The copolymerization may be conducted at elevated temperatures such as from 70 to 120°c, preferably from 90 to 110°C.

Preferably, the copol ymerization is initiated by heating the mixture to 70 to 120°C, preferably from 90 to 110°C.

In a. preferred embodiment of the method of invenL.l.on, s Lep .l.) comprises the steps of reactants, deoxygenizing the mixture, heating the the present mixing the mixture and then cooling the mixture. Afterwc.rds, the polymer may be dissolved and st.l.r:.::ed overnight. The formed solid may be recovered, preferably using centrifugation.

In a preferred embodiment of the method of the present invention, step ii) includes the addition of a base to the 24 CA 03166158 2022-7-26 polymer (e.g. NaOH). Preferably, the base is reacted with the polymer at elevated temperature, preferably between 50°C and 70°C, such as 60°C until almost all solids is dissolved. The resulting suspension may be acidified (e.g. pH <2).

Afterwards, the reaction wixture may be extracted with an organic solvent such as ethyl acetate. The orqanic layer may be extracted with a sodium hydroxide solution. The aqueous solution may be again extracted with an organic sol vent such as ethyl acetate and then dried to obtain the purified amphiphilic polymer. -:::'he polymer may be further purified (step iii) . Preferably, the polymer is further purified by extracting the polymer with n-hexane or n-heptane. The extraction can be performed at concentrations of greater than 10 g/L, preferably 100 g/1.

Furthermore, an additional purification step of the amphiphilic polymer may be added between steps i) and ii). In this additional purification step, the crude reaction product of the polymerization is dissolved and precipitated. In a preferred embodiment, the sol vent is dichloromethc1ne c1nd the polymer is precipitated using a mixture of methanol/heptane or acetoni trilc/ iso-propanol. The mixtures used may contain for example 95/ 5% (v/v%) methanol/heptane, 10/ 90 (v /v%) acetoni trile/ iso-propanol or 5/ 95 (v /v%) acetoni trile/ isopropanol.

In a preferred embodiment, the precipitation mixture is added at temperatures of -10 Lo 10°C, preferably -5 to 5°C.

The purity of the amphiphilic polymer after hydrolysis and workup can be measured by 1 =..i NMR.

In the method of the present invention, the micelle is formed by forming a solution containing the amphiphilic polymer.

Preferably, U1e mlcelle is formed in an aqueous solution. Costabilizers may be added t.o the amphiphilic polymer to improve rnicelle formation.

The peptides to be used in step iv) may be synthesized using state of the art solid phase chemistry.

CA 03166158 2022-7-26 ~he peptides may be covalently linked to the micelle or noncovalently associated.

In a preferred embodiment of the method of the invention, the peptides are coupled to the surface nanoparticle using peptide coupling techniques known art, e.g., carbodiimidc or succinimide coupling. present of the in the In a specifically preferred embodiment of the method of the present invention, the peptides are coupled to the surface of the nanoparticle via EDC chemistry (1-Ethyl-3-(3- dimethylaminopropyl)carbodiimide) in aqueous phase.

The resulting nanoparticles may be purified using intcnsi ve washing and filtration steps to remove the coupling reagent(s) and any low molecular weight components.

In a preferred embodiment, the method of producing a nanoparticle comprises: a) obtaininq a hydrophobic core nanoparticle, b) obtaining an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less, preferably using radical copolymerization, c) optionally purifying the amphiphilic polymer, d) mixing of the hydrophobic core nanoparticles and the amphiphilic polymer to form micelles, e) adding at least one peptide to form l:.he nanoparticles.

The discussion of steps i) to iii) and iv) above also applies to steps b) to d) and e) respectively.

The hydrophobic core of step a) can be synthesized using appropriate reactants in solution. In a preferred embodiment of the method of t~e present invention, the hydrophobic core can be synthesized using metal salts and salts of carboxylic acjds as reactants in the presence of organic solvents.

Preferably, the reaction is conducted at elevated temperatures under oxygen restriction. 26 CA 03166158 2022-7-26 The micelle can be formed by the arrangement of the amphiphilic copolymer around the core in step e) . Preferably, step d) comprises the sub-steps of solubilising the amphiphilic polymer and the core particles, removing the solvent until a thin film is formed, adding a basic aqueous solution at increased temperature and ambient pressure to form an aqueous colloidal dispersion, diluting the solution and optionally filtering it. Afterwards, several washing steps may be applied.

Examples The invention is illustrated by the following examples, which describe in detail the synthesis of nanoparticles according to the present invention.

These examples shoula not be considered as limiting the scope of the invention, but as illustrating it.

Example 1: Preparation of superparamagnetic iron oxide crystalline cores (SPIONs) The synthesis of an iron oleate complex is schematically shown in Figure 1.

In a first step, an iron oleate complex was synthesj 7.ed by mixing oleic acid, sodium hydroxide and iron chloride under reflux at 70°C. The product was purified by several washing steps in a separation funnel, and then dried with sodium sulphate and concentrated in a rotary evaporator. This resulted in iron oxide crystalline cores (Figure 1) In a second step (Figure 2), the iron oleate complex was dissolved in 1-ocladecene a.L room tenpera.ture and stirred until complete dlssoluLlon. Then, oleic acid was added, deoxygenated and heated for 3 hours at 300°C for the formation of iron oxide nanocrystals.

After cooling, the product was purified by several washing steps using magnetic separation and acetone/tetrahydrofuran (THF) . Purified SPIONS were diluted in chloroform and 27 CA 03166158 2022-7-26 concentrated in a rotary evaporator resulting in SPIONs with narrow size distribution and good crystall1n1ty.

Example 2: Preparation of low molecular weight poly(maleic acid-ait-1-octadecene) (LM-PMAcOD) ~he synthesis of low molecular weight poly(maleic acid-all-1- octadecene) (LM-PMAcOD) was achieved in a two-step process which is schematically shown in Figures 3 and 4.

In a first step, maleic anhydride (48.9 mmol) and 1-octadecene (48.? mmo]) were dissolved in 10 ml l,4 dioxane (inhibitor of l, 4-d.1 oxane was previously removed by filtering it over 3CJ aluminum oxide). Afterwards, 5.79 mmol AIBN (2,2'-Azobis(2- methylpropionitrile)) was added. The flask was equipped with a cooler and subsequently flushed with nitrogen and kept on a nitrogen overpressure. The mixture was heated to 100 °C while stirring. 1 hour after the heating was started, the heating plate was removed together with the stoppers; exposing the reaction to air. The mixture was cooled to room temperature for two days while stirring. The product was purified by coevaporation with dichloromethane and precipitated with isopropanol and acetonitrile. Low molecular weight poly(maleic anhydride-al t-1-octadecene) (LM-PMAOD) with cJ. number uverage molecular weight (Mn) of 2,500 to 4,000 g/mol was obtained.

In a second step, LM-PMAOD was hydrolysed to poly(maleic acidal t-1-octadecene) (LM-PMAcOD) in sodium hydroxide solution. An acid-base extraction with H2S04 , ethylacetater and NaOH was performed for the purification of the product and to remove impurities such as residual 1-octadecene. The product was dried over magnesium sulphate, co-evaporated with chloroform and finally purified by solid- liquid extraction in n-heptane (Figure 4). 'l'he number average molar mass (Mn) mass (Mw) of the polymer obtained permeation chromatography. and the mass average molar was determined using gel A sc1mple of 1.5 mg of LM~PMAcOD was dissolved in 1.0 mL of TIIF (devoid of stabilizer) and submitted Lo GPC. Polystyrene was 28 CA 03166158 2022-7-26 used as calibration standard. Tetrahydrofuran was used as a eluent and the flow rate was 1 ml/min. The temperature was set to 30°C.

The number average molar mass (Mn) of the LM-PMAcOD produced was 1540 g/mol and the mass average molar mass (Mw) was 2410 g/mol. Hence, a PDI value of 1.56 was calculated for tho sample, which is characteristic for a non-controlled free radical polymerization Example 3: Polymer coating of SPIONs polymer produced ( sec Figure 8) . via The polymer coating of SPIONs is schematically shown in Figure 5.

Example 3a: 100 mg LM-PMAcOD obtained in Example 2 was dissolved in 4 mL chloroform in a 100 mL round bottomed flask.

The mixture was heated until the polymer was fully dissolved. 3.3 mL of the oleate-SPION solution obtained in Example 1 was added to the mixture and subsequently evaporated at <10 mbar for 15 minutes at 40°C on the rotavap with 200 RPM. Then, 10 mL 5 mM NaOH was added to the mixture and stirred on the rotavap for 15 minutes at 50°C un-:=il all black solids were dissolved. The solution was diluted 8 times us2-ng- 70 mL 25 mM NaOH to dissolve the entire polymer. The obtained solution was stirred on the rotavap for 15 minutes, resulting in a brown solution.

The product was filtered over a O. 45 μ.m and a O. 2 μm PES filter. Afterwards, the probe was purified by tangential flow filtration (TFF) Example 3b: The same procedLlre was performed with commercially available 30-50 kDa polymer (#419117 Merck) after hydrolization according to Example 2. As the removal of the unbound polymer from the polymer coated SPIONs by TFF was insufficient, additional magnetic separation was carried out using a Miltenyi column to purify the PMAcOD-SPION batch MX0194. 29 CA 03166158 2022-7-26 Example 4: Peptides and peptide coupling The peptide coupling and nanoparticle synthesis lS schematically shown in Figure 6.

The synthesis of Lhe peptides was accomplished via Fmoc chemistry from the C to N direction using solid phase peptide synthesis (SPPS) The alpha amino group of each amino acid was protected with a fluoren-9-ylmethoxycarbonyl (Fmoc) group, while side chain functional groups were also blocked with various appropriate protective groups.

In general, the SPPS consists of repeated cycJes of N-terrninal deprotection followed by coupling reactions. The first Fmocprotected amino acid was coupled to the resin. Afterwards, the amine group was deprotected with a mixture of piperidine in dimethylformamide ( DMF) , and then coupled with the free acid of the second Fmoc-protected amino acid. The cycle was repeated until the desired sequence was obtained. The resin was washed between each step. The completion of each coupling reaction was mon~tored by a qualitative ninhydrin test. In the last step of the synthesis, the crude peptide-resin was successively washed with DMF and methanol, and dried. Then, the protective groups were romovod from the peptide and the peptide was cleaved from the resin using trifluoroacetic acid (TFA). The obtained crude peptide was isolated by ether precipitation from the cleavage mixture.

Further, the peptide was purified through preparative HPLC to reach purity requirements, and the counter ion TFA was replaced wL Lb cbJ uri de by using an appropriate sol vent-buffer system. Finally, the purified peptide was lyophilized.

The peptides used have an amino acid at the N-terminus and a free acid (HCl salt) at the C-terminus and have a length of 15 amino acids.

Characterization of the free peptides (starting materials) was performed by LC-MS.

The peptide sequences and calculated monoisotopic mass used in the examples of the p~esent application are shown in Table 1.

CA 03166158 2022-7-26 Table 1: Peptide sequences and monoisotopic mass SEQ ID Sequence Molecular Monoisotopic mass NO: formula (theoretical) (Da) 1 LNSKIAFKIVSQEPA C7c,H1 ;,c,N1 g0;,;, 1643.9 2 TPMFLLSRNTGEVRT C14H124N22O23S 1720.9 3 REGIAFRPASKTFTV C 16Hi22N 220n 1678.9 The molecular weight of the peptides was measured by multimode electrospray atmospheric pressure chemical ionization mass spectrometry.

The peptides were coupled to the surface of the micelle obtained in Example 3a using 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide acid/sodium tetraborate decahydrate (EDC) chemistry (SBB) buffer. in boric EDC in SBB buffer was added to the raicelle oblained in Example 3. After 15 Minutes at RT, the peptides were added and the reaction mixture was stirred for 2 hours and 15 minutes at RT.

The resulting nanoparticle solution was filtered and purified by tangential flow filtration (TFF) purification.

Example 5: Characterization of the nanoparticles The nanoparticles obtained in Example 4 were further characterized using a variety of analytical methods.

Characterization TEM and SAXS. of the iron oxide TEM measurements core were was performed performed on using the nanoparticles dispersed in 5% (w/v) D-mannitol, 5 mM TRIS and 6 mM L-lactic acid.

The calculated particle size results based on TEM analysis of the nanoparticles produced in Example 4 are summarized in Table 2. Representative TEM images are shown in Figure·;. 31 CA 03166158 2022-7-26 Table 2: Average iron oxide core size results based on TEM analysis TPC Average iron oxide Standard deviation core size (nm) (%) TPC0002 9.74 1.04 SEQ ID NO:1 TPC0003 9.45 0.92 SE,Q ID NO:2 TPC0005 9.80 0.96 SEQ ID NO:3 SAXS measurements dispersed ic 5% (w/v) acid. were performed on the nanoparticles D-mannitol, 5 mM TRIS and 6 ruM L-lactic The calculated particle s~ze results based on SAXS analysis of the nanoparticles produced in Exa:nple 4 are summarized in Table 3.

Table 3: Average iron oxide core size results based on SAXS analysis ------- TPC Average iron oxide Standard deviation SEQ ID NO: core size (nm) (%) TPC0002 9.8 1.1 SEQ lD NO:1 TPC0003 10.0 SEQ ID NO:2 1.1 TPC0005 9. 8 1.1 SEQ ID NO:3 Characterization of particle size and distribution was performed by dynamic light scattering (DLS) The hydrodynam~c diameter (z-averaqe) and polydispersity index were determined using a Malvern Zetasizer Nano ZS or equivalent in lm i modal mode.

Those measurements were performed on produced in Example 4 dispersed in 5% 5 mM TRIS and 6 mM L-lactic acid. the (w/v) nanoparticles D-mannitol, The results are summarized in Table 4. From these results, it can be observed that the formulation stabilizes the particles and can reduce the percentage of large particles. 32 CA 03166158 2022-7-26 Table 4: Size distribution results based on DLS analysis TPC z-average polydi.spersity D10 (nm) Dso (nm) D90 (nm) SEQ ID NO: (nm) index (%) TPCOOO?. 23 15.8 24.0 3'/.6 0.13 SEQ ID NO:l TPC0003 25 16.8 25.l 39.3 0.17 SEQ ID NO:2 TPC0005 SEQ 26 16.4 24.9 53.9 0.25 ID N0:3 The surfuce charge of the particles was analyzed by measuring the zeta potential at pH 6 to 7 (pH during measurement) using a Malvern Zetasizer Nano ZS instrument. These measurements were performed on the nanoparticles produced in Example 4 dispersed in 5% (w/v) D-mannitol, 5 rnM TRIS and 6 mM L-lactic acid.

The results are summarized in Table 4.

Table 4: Zeta potential results Zeta Zeta TPC potential deviation Conductivity Result SEQ ID NO: (mS/cm) quc1lity (mV) (mV) TPC0002 -39.5 5.38 SE.:Q :lD NO:1 ··--··-· TPC0003 SEQ -39.1 5.95 ID NO:2 TPC0005 SEQ -30.1 4.63 ID NO:3 The total polymer content was peptides HCl. The were hydrolyzed, and the PMAcOD was extrc.cted ------ --- - 1. 30 Good 1. 44 Good 1. 42 Good determined using GPC. The particles destroyed in 6 M with ethyl acetate after addition of EDTA. After evaporation of sol vent, the residue was re-dissolved in a THF/acetic acid mixture before analysis.

The results are summarizec in Table 5. 33 CA 03166158 2022-7-26 Table 5: Total polymer content TPC Total polymer content SEQ ID NO: (mg/mL) TPC0002 1. 62 SEQ ID NO:l TPC0003 1. 42 SE;Q ID NO: 2 TPC00OS 1. 36 SEQ ID NO:3 The spectroscopic properties of the nanoparticlcs wore determined by Fourier-transform infrared spectroscopy (FTIR).

The assignments of the major absorption bands are summarized in Table 6.

Table 6: Proposed description of IR vibrational modes for the nanoparticles Frequency of absorption bands ( cm-1 ) 3500 - 3000 2920-2919, 2851-2850 1646-1642 1534-L'J44 1402-1395 574-569 Example 6: polymer Effect Description of the IR vibrational modes Broad, carboxylic acid 0-H stretch Alkane C-H stretch C=O stretch, weakly coupled to C-N stretch and N-H stretch C-N stretch, strongly coupled with N-H bending Carboxylic acid O-H bending Fe-O bond of different sizes of amphiphilic The effect of different sizes of arnph..Lph..Llic polymer in the nanoparticles of the present invention was studied. SPIONs were coated w-ith PMAcOD polymers with a nrnnber average molecular weight of 3100, 4800 and 5900 g/mol.

These polymers were synthesized, after which lhey were employed oleu. te-SPIONs. l\.fter coating the using TFF purification. 34 CA 03166158 2022-7-26 purified and characterized, in a coating reaction of excess polymer was removed a) Synthesis of poly(maleic acid-aLt-1-octadecene) with different molecular weights (PMAcOD) Three different lengths of poly (maleic acid-al t-1-octadecene} were synthesized by free radical polymerization of maleic anhydride and 1-octadecene. The reaction was carried out in 1,4-dioxanc using 2,2'-Azobis(2-mcthylpropionitrilc) iJ.G initiator. Polymerization was initi~ted by heating the mixture to 100°C. Secondly, after purification, the polymer was hydrolyzed using a sodium hydroxide solution to obtnin PMAcOD.

The polymers with higher molecular performing the polymerization conditions and/or executing the decreased amount of initiator. weight were synthesized by under more concentrated polymerization with a The amount of reactants used in the synthesis of the three polymers is summarized in TaDle 7.

Table 7: Amount of reactants Length Maleic 1- 1,1- (g/mol) anhydride octadecene AIBN (g) dioxane ( g) (g) (mL) PMAcOD3100 3100 4. 8 12.36 1.004 40.8 PMAcOD4800 4800 4. 8 1:?. 18 0.950 10.0 PMAcOD5900 5900 1. 8 12.18 0.500 10.0 The purity of the polymer after hydrolysis of the maleic anhydrides and workup was measured by 1H-Nt1R (400 Hz, 30 mg sample, 10 mg benzoic acid standard, /00 μL D-chloroform) and the length of polymer was analyzed by gel permeation chromatography (Agilent PL-gel mixed-D, 300 x 7.5 mm ID, 5 μm, 2 mg/mL in THF/acetic acid (90/10), 15 min run). b) Effect of different lengths of amphiphilic polymer The PMAcOD with various lengths were used to coat oleaLeSPIONs.

First, the coatings were performed using the same polymer-toSPION weight ratio. To find the best coating conditions, the polymer-to-SPION molar ratio was kept constant. The amounts of CA 03166158 2022-7-26 aggregates were compared. The method with the least aggregates was repeat:ed and subsequently purj fied using '11FF. 'rhe removal of polymer and the amount of aggregates was monitored during TFF using size exclusion chromatography (SEC).

Oleate-SPIONs were coated with PMA.cOD3100, PMA.cOD4800 and PMAcOD5900) to dotermino the optimal polymcr/SPION rat~o.

To coat the oleate-SPIONs the polymer and the nanoparticles were dissolved in chloroform. Subsequently, the chloroform was evaporated. In the final step of the coating procedure, an aqueous sodium hydroxide solution wa~ added Lu Lhe :[lask and mixed at 50°C. For PMAcOD3100 100 mg polymer was used. For PMAcOD4800 coatings with 100 mg polymer and 145 mg polymer were compared. For PMA.cOD5900 coatings with 100 mg polymer and 1 77 mg polymer were compared. This way, equal amounts of monomer were compared to equal amounts of polymer chains with respect to PMAcOD3100.

Ry using size exclusion chromatography, it was determined which condition resulted in the least amount of aggregates.

The results are summarized in Table 8.

Table 8: Overview of aggregates produced by the coating of SPIONs with different polymers Equivalents of Length Amount of polymer Aggregates (g/mol) polymer (mg) compared to ( % ) PMAcOD3100 PMA.cOD3100 3100 100 1 5.9 PMAcOD4800 4800 100 0.65 5.2 145 0.93 5.9 PMAcOD5900 5900 100 0.53 16.0 177 0.93 '/. 8 c) Effect of different polymer lengths after purification Oleate-SPIONs were coated using the same protocol as used before. For all polymers the same amount of polymer cha-ins was used. After coating, the PMAcOD-SPIONs were purified by TFF.

Due to the difficulty of removing the final amounts of polymer PMA.cOD5900, it was decided to also try this coating wiU1 36 CA 03166158 2022-7-26 0.15 g polymer (0.79 equivalents compared to standard experiment with PMAcOD3100).

Using SEC it was polymer was left corcprised 5.9% determined how many aggregates and how much in the sample. After coating, PMAcOD3100 aggregates, PMAcOD4800 comprised 6.2% aggregates and PMAcOD5900 comprised 10.7% oggrcgates. This matched with the data described in the previous section.

Next, the PMAcOD-SPIONs were purified by TFF. The particles were loaded onto the membrane, after which they were rinsed with 5 mM NaOH/45 rnM NaCl. Every 10 DVs (for PMAcOD3100) or 20 DVs (for PMAcO4800 and PMAcOD5900) (DV ...., diafiltration volume in the TFF purification), a sample SEC (afterwards). During the TFF process-samples were taken to keep polymer and increase in aggregates. was taken and measured by purification, also intrack of the decrease in 'l'hc results arc summarized in Table 9.

Table 9: Overview of TFF experiments Run Amount of Aggregates Aggregates polymer at start after TFF DVs used (mg) (%) (%) 1 PMAcOD3100 100 5.9 7. 0 160 2 PMAcOD4800 100 6.2 7.3 160 3 PMAcOD5900 177 10.7 10.7 150 4 150 10.9 10.4 110 The TFF products of runs 1, 2 and 4 were filtered over a 0.2 μm filter. Run 1 was also filtered over a 0.1 μrn filter to decrease the amocnt of aggregates.

Before and after filt~ation of the samples, dynamic light scattering (DLS) measurements were performed to determine the Z-average diameter and the polydispersi ty index (PDI) . 1\.11 batches of PMAcOD-coated SPIONs showed a z-average diameter of 26 to 20 nm with a PDI of 0.25 to 0.33 (see Table 11).

The amounts of iron were determined using atomic absorption spectroscopy (AA.S) to be 38 to 50 =ng after filtration, which corresponds to an iron recovery of 83 to 110 %. 37 CA 03166158 2022-7-26 The results are summarized in Table 10.

Table 10: DLS data; before and after filtration.

Run Product Unfiltered Filtered -- -- ------ -- -- ------------ -- -------- - ------- z- z- Iron Iron average PDI average PDI content recovery (nm) (nm) (mg) ( % ) 1 PMAcODJl00 31.7 0.382 26.8 0.256 38 83 - SPIONS 2 PMAcOD4800 28.8 0.360 27.0 0.325 50 110 - SPIONS 3 PMl\cODS 9 0 0 - SPIONS 32.1 0.36'/ 2'7.6 0.251 46 101 Example 7: Comparison of purification of PMAcOD-SPIONs with polymers having different molecular weight SPIONs coated with a commercial high molecula::::- weight PMAcOD (Mn of 30,000 to 50,000 g/mol) and a low molecular weight PMAcOD (Mn of 3,000 to 5,000 g/mol) were produced as descri:Oed in Examples 1-4. Afterwards, tangential flow filtration (TFF) purification was used to remove unbound material. TFF is the method of choice for the purification of the coated SPIONS because it can be scaled easily. Size exclusion chromatography (SEC) analys:is of retentate and permeate samples was performed to monitor the TFF-purification process. The purification efficiency using TFF of the SPIONs coated with high and low molecular weight polymers was compared. a) Purification of high molecular weight PMAcOD-SPIONs In a first step, a sample of the crude HM-PMAcOD-SPIONs was analyzed using SEC prior to purification by TFF (crude sample, see Figure 9) . The batch of crude IIM-PMAcOD-SPIONs showed a small shouldE::r left of LhE:: main HM:-PMAcOD-SPION peak (RT: 15.541), indicating that this batch contained a minimal amount of large aggregates, with 21. 2% (a/a) o-"' ·unbound polymer free (RT: 16.698) in the dispersion.

Subsequently, the high molecular weight PMAcOD-SPION sample was filtered by TFF using a 300 kDa TFF membrane in order to separate the HM:-PMAcOD-SPIONs after polymer coating from unbound polymer molecules. As illustrated in Figures 9 and 10 38 CA 03166158 2022-7-26 no separation was achieved but both HM-PJ'v.lAcOD-SPIONs and HMPMAcOD polymer was contained in the permeate after filtration.

Thus, several options were tested to see if this could be reduced. However, none succeeded. The retention of the HMPMAcOD- SPIONs was loo low to obtain a good separation between SPIONs and polymer without losing too much product. A membrane with a decreased pore size polymer coated SPIONs but of 100 kDa allowed retention of the at the same time led to retention and concentration of the polymer (illustrated in Figure 11).

In concluslon, lL has been found that neither filtration with a 300 kDa TFF membrane nor filtration with a 100 kDu. TFF membrane allows for the purification of HM-PMAcOD-SPIONs from unbound HM-PMAcOD material. b) Purification of low molecular weight PMAcOD-coated SPIONs In a second approach, SPIONs were purified t~--ie low molecular weight PMAcOD-coated using TFF (100 kDa filter membrane).

Again, size exclusion chromatography analysis of retentate and permeate samples was performed to monitor the TFF purification process. Results are shown in Figure 12 for two batches (batches MX0373A and MX0374A) The use of LM-PMAcOD (Mn of 3,000 to 5,000 g/mol) showed efficient diffusion of the unbound polymer over a 100 kDa TFF membrane and removal of more than 90% of unbound polymer from the LM-PMAcOD-SPIONs.

The SEC chromatograms of the products after coating (MX0373A and MX0374A), TFF' (100 kDa membrane) purification (MX0373E and MX0374E) and final 0.1 pm filtration (MX0373F and MX0374P) are shown in Figure 13.

Furthermore, the SEC data ot samples after TFF purification (100 kDa filter membrane; batches· MX0373E and MX0374E) and after TFF purification followed by 0.1 μm filtration (batches MX0373F and MX0374F) is shown in Table 12 below. 39 CA 03166158 2022-7-26 Table 12: ------ --------- 20- Aggregates % un-bound Product i SPIONs (a/a) (a/a) polymer removec::_ MX0373E 89.0 11. 0 80.4 MX0373F 89.5 10.5 -- --- - MX0374E 88.7 11. 3 78.9 MX0374F 89.2 10.8 As can be seen from the data provided, it was possible to efficiently purify the LM-PMAcOD-SPIONs by TFF, whereas the purification of the HM- PMAcOD-SPIONs was inefficient and did not result in a pure product.

Example 8: In-vivo safety after intravenous injection in mice of low molecular weight polymer based micelles containing an iron oxide core compared to high molecular weight polymer based micelles containing an iron oxide core a) The batch MX0194 produced in Example 3b was injected intravenously in female CDl mice at a dose of 1 mmol Fe/kg bw and 2 mmol Fe/kg bw. One mouse died at 2 mmol Fe/kg which was defined to be test item related. Mice were euthanized 14 d after injection. Significant increases in absolute organ weight compared to matched controls were found ( see table 13) which was defined to be an adverse effect of test item injection. b) A PMAcOD-SPION batch produced according to Example 3a was in7ected intravenously in female CDl mice 3 times at a dose of 1 mmol Fe/kg bw (3 mmol Fe/kg bw in total) with 14 days between injection 1 and 2 and injection 2 and 3. Animals were euthanized 24 hours after the last injection. Only a slight bul nu L 0..i.gnl.Li.canl lncrease ln llver weighl was found and no increase in lung weight (see table 13).

The influence on organ weight by high molecular weight polymer based nc:mopc1rticles is related to a long-term adverse effect CA 03166158 2022-7-26 of the high molecular weight polymer due to the fact that the -iron core was similar for the batches produced in Example Sa and 8b.

The results of the comparative study are summarized in Table 13.

Table 13: ··-·- - .. ·····--·-···---·---· liver weight lung weight increase increase [weight %] [weight %] example 8a 1 mmol Fe/kg 17.4* 2.9 n=5 example 8a 2 mmol Fe/kg 25.0** 26.2** n=4 example Bb 3 mmol Fe/kg 5.7 0.7 n=l2 organ weight increase is calculated from absolute organ weight were absolute organ weight of body weight ::natching control animals is given as 100%. *p<0.05; **p<0.01 One Way Anova with Dunnett The low molecular weight polymer was thus shown to have a lower toxicity than the high molecular weight polymer. 41 CA 03166158 2022-7-26

Claims (3)

1. CA 3,166,158 CPST Ref: 40831/00001 42 CPST Doc: 1380-0991-7191.3 Claims 1. A nanoparticle comprising a) a micelle comprising an amphiphilic polymer with a number average molecular weight (Mn) of 6,000 to 1,000 g/mol, and b) at least one peptide comprising at least one T cell epitope.
2. 2. The nanoparticle of claim 1, wherein the nanoparticle further comprises a solid hydrophobic core which is at least partially coated by the micelle, wherein the core comprises a traceable inorganic material selected from the group comprising iron oxide, CdSe/CdS/ZnS, silver and gold. 3. The nanoparticle of claims 1 or 2, wherein the peptide is associated with the outside of the micelle. 4. The nanoparticle of any one of claims 1 to 3, wherein the amphiphilic polymer has a main hydrophilic poly-maleic anhydride backbone having hydrophobic alkyl side chains. 5. The nanoparticle of any one of claims 1 to 4, wherein the amphiphilic polymer comprises the following building block: wherein R is a hydrocarbyl group or a substituted hydrocarbyl group. 6. The nanoparticle of claim 5, wherein R is a C4 to C22 alkyl group. 7. The nanoparticle of claim 5, wherein R is a C8 to C20 alkyl group. 8. The nanoparticle of claim 5, wherein R is a linear alkyl group. 0 0 R OH HO n CA 3,166,158 CPST Ref: 40831/00001 43 CPST Doc: 1380-0991-7191.3 9. The nanoparticle of claim 8, wherein R is a linear C11 to C17 alkyl group. 10. The nanoparticle of claim 8, wherein R is a linear pentadecyl group. 11. The nanoparticle of any one of claims 1 to 10, wherein the amphiphilic polymer is poly(maleic acid-alt-1-octadecene) , poly(maleic acid-alt-1-dodecene), or poly(maleic acid-alt-1- tetradecene), and the number average molecular weight of the polymer is from 6,000 to 1,000 g/mol. 12. The nanoparticle of claim 11, wherein amphiphilic polymer is poly(maleic acid-alt-1- octadecene). 13. The nanoparticle of any one of claims 1 to 12, wherein the peptide is covalently linked to the micelle. 14. The nanoparticle of claim 13, wherein the peptide is covalently linked to the micelle using carbodiimide or succinimide coupling. 15. The nanoparticle of any one of claims 1 to 12, wherein the peptide is non-covalently associated. 16. The nanoparticle of any one of claims 1 to 15, wherein the peptide comprises 9 to 60 amino acids 17. The nanoparticle of any one of claims 1 to 15, wherein the peptide comprises 10 to 20 amino acids. 18. The nanoparticle of any one of claims 1 to 17, wherein the nanoparticle is negatively charged at a pH of 6 to 7. CA 3,166,158 CPST Ref: 40831/00001 44 CPST Doc: 1380-0991-7191.3 19. The nanoparticle of any one of claims 1 to 18, wherein the nanoparticle has a hydrodynamic diameter between 100 and 10 nm as measured by dynamic light scattering. 20. The nanoparticle of any one of claims 1 to 18, wherein the nanoparticle has a hydrodynamic diameter between 50 and 10 nm as measured by dynamic light scattering. 21. The nanoparticle of any one of claims 1 to 18, wherein the nanoparticle has a hydrodynamic diameter between 20 and 40 nm as measured by dynamic light scattering. 22. A pharmaceutical composition comprising the nanoparticle of any one of claims 1 to 21. 23. A pharmaceutical composition for use in suppressing a specific immune response comprising the nanoparticle of any one of claims 1 to 21. 24. The pharmaceutical composition for use in suppressing a specific immune response of claim 23, wherein said response is an autoimmune disease. 25. The pharmaceutical composition for use in suppressing a specific immune response of claim 23, wherein said autoimmune disease is Pemphigus vulgaris, Pemphigus foliaceus, Epidermolysis bullosa Acquisita, Bullous pemphigoid, Cicatricial pemphigoid, Goodpasture syndrome, Microscopic polyangiitis, Granulomatosis with polyangiitis (Granulom. Wegener), Thrombotic thrombocytopenic purpura, Immune thrombocytopenic purpura, Uveitis, HLA-B27- associated acute anterior uveitis, Multiple sclerosis, Neuromyelitis optica, Type I diabetes, Narcolepsy with or without cataplexy, Celiac disease, Dermatitis herpetiformis, Allergic airways disease/Asthma, Myasthenia gravis, Hashimoto thyreoiditis, Autoimmune thyroid disease, Graves disease, Autoimmune thyroid disease, Autoimmune Hypoparathyroidism, Autoimmune thyroid disease, Antiphospholipid syndrome, Autoimmune Addison's Disease, Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating, Polyneuropathy, Guillain–Barré syndrome, Autoimmune neutropenia, Linear morphea, Batten disease, Acquired hemophilia A, Relapsing polychondritis, Isaac´s syndrome (acquired neuro-myotonia), Rasmussen encephalitis, Morvan syndrome, Stiff-person syndrome, Pernicious anaemia, Vogt–Koyanagi– CA 3,166,158 CPST Ref: 40831/00001 CPST Doc: 1380-0991-7191.
3. 3 Harada syndrome, Primary biliary cirrhosis, Autoimmune hepatitis type I, Autoimmune hepatitis type II, Systemic lupus erythematosus, Rheumatoid arthritis, Polymyositis/ Dermatomyositis, Sjögren syndrome, Scleroderma, Vitiligo, or Alopecia areata. 26. A method of producing a nanoparticle comprising: i) obtaining an amphiphilic polymer with a number average molecular weight (Mn) of 6,000 to 1,000 g/mol, ii) optionally purifying the amphiphilic polymer, iii) forming micelles of the amphiphilic polymer, and iv) adding at least one peptide to form the nanoparticles. 27. The method of claim 26, wherein step i) is a radical copolymerization synthesis step. 28. The method of claim 26, wherein the radical copolymerization synthesis step uses 2,2′- Azobis(2-methylpropionitrile) as a radical initiator.